Patient groups’ pandemic pain; plus voters’ rights and synthetic lethality: a BioCentury podcast

The pandemic has hurt patient groups that have heavily relied on in-person events for fund-raising and patient outreach. On the latest BioCentury This Week, BioCentury’s editors discuss the consequences of the groups’ shrinking budgets on patients and the biopharma ecosystem, plus the biopharma industry’s response to new and impending voter-related legislation, AACR’s synthetic lethality standouts and the latest SPAC deals.

Washington Editor Steve Usdin explains how shrinking budgets for patient groups has set back scientific research, hurt vulnerable patients and undermined organizations that have become key cogs in the wheel of biomedical progress. ...